Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 79
- Registration Number
- NCT00850395
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 129
- Registration Number
- NCT00827112
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 12
- Registration Number
- NCT00821535
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 45
- Registration Number
- NCT00812318
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
- Conditions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00801515
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 103
- Registration Number
- NCT00791700
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Phase 4
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00782301
- Locations
- 🇵🇱
Pfizer Investigational Site, Bydgoszcz, Poland
Maraviroc Compassionate Use
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00719823
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT00717067
- Locations
- 🇩🇪
Pfizer Investigational Site, Muenchen, Germany
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 35
- Registration Number
- NCT00708110
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath